Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It is estimated that one-third of our country’s population has some form of these disorders
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
